5.81
Astria Therapeutics Inc stock is traded at $5.81, with a volume of 188.85K.
It is up +1.40% in the last 24 hours and up +17.14% over the past month.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
See More
Previous Close:
$5.73
Open:
$5.8
24h Volume:
188.85K
Relative Volume:
0.40
Market Cap:
$322.24M
Revenue:
-
Net Income/Loss:
$-72.89M
P/E Ratio:
-2.4008
EPS:
-2.42
Net Cash Flow:
$-68.47M
1W Performance:
+6.80%
1M Performance:
+17.14%
6M Performance:
-34.57%
1Y Performance:
-35.44%
Astria Therapeutics Inc Stock (ATXS) Company Profile
Name
Astria Therapeutics Inc
Sector
Industry
Phone
617-349-1971
Address
22 BOSTON WHARF ROAD, BOSTON
Compare ATXS with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ATXS
Astria Therapeutics Inc
|
5.81 | 322.24M | 0 | -72.89M | -68.47M | -2.42 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
Jan-31-25 | Initiated | JMP Securities | Mkt Outperform |
Jul-29-24 | Initiated | TD Cowen | Buy |
Mar-28-23 | Initiated | Evercore ISI | Outperform |
Astria Therapeutics Inc Stock (ATXS) Latest News
(ATXS) Trading Report - news.stocktradersdaily.com
Astria Therapeutics to Participate in Upcoming Oppenheimer Innovators in Immunology & Inflammation Summit - BioSpace
Astria Therapeutics to Participate in Upcoming Oppenheimer Innov - GuruFocus
Astria CEO Discusses Breakthrough Dermatology Treatments at Major Oppenheimer Summit - Stock Titan
HC Wainwright Reaffirms “Buy” Rating for Astria Therapeutics (NASDAQ:ATXS) - Defense World
Brokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) Target Price at $30.00 - Defense World
Astria Therapeutics (ATXS) Receives Reiterated Buy Rating and $1 - GuruFocus
Astria Therapeutics (ATXS) Reports Promising Results for Navenib - GuruFocus
Astria Therapeutics Announces Positive Initial Results from the - GuruFocus
Astria Therapeutics Says New Data Back Navenibart Dose Regimen for Hereditary Angioedema - MarketScreener
Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress - Yahoo Finance
California State Teachers Retirement System Increases Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Two Sigma Investments LP Sells 2,042 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Astria Therapeutics Stockholders Approve Key Amendments - TipRanks
Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Cantor Fitzgerald Estimates ATXS FY2026 Earnings - Defense World
Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Annual Congress - BioSpace
(ATXS) Investment Report - news.stocktradersdaily.com
Astria Therapeutics to Present at Upcoming European Academy of A - GuruFocus
Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Annual Congress | ATXS Stock News - GuruFocus
Jane Street Group LLC Has $233,000 Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
BNP Paribas Financial Markets Acquires Shares of 5,572 Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Astria Therapeutics Announces Inducement Grants Under Nasdaq Lis - GuruFocus
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ATXS Stock News - GuruFocus
ProShare Advisors LLC Invests $140,000 in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Deutsche Bank AG Buys 13,986 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Citizens JMP maintains $25 target on Astria Therapeutics stock By Investing.com - Investing.com Canada
Astria Therapeutics to Present at Upcoming Jefferies Global Healthcare Conference - Business Wire
Janus Henderson Group PLC Takes Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Astria Therapeutics to Present at Upcoming C1 Inhibitor Deficien - GuruFocus
Astria Therapeutics to Present at Upcoming C1 Inhibitor Deficiency and Angioedema Workshop | ATXS Stock News - GuruFocus
Astria Therapeutics to Present at Upcoming C1 Inhibitor Deficiency and Angioedema Workshop - Business Wire
Northern Trust Corp Has $4.10 Million Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Astria Therapeutics to Present at Upcoming Eastern Allergy Confe - GuruFocus
Astria Therapeutics to Present at Upcoming Eastern Allergy Conference | ATXS Stock News - GuruFocus
New Clinical Data: Astria's Navenibart Cuts Hereditary Angioedema Attack Severity, Reduces Rescue Med Usage - Stock Titan
Astria Therapeutics to Present at Upcoming Eastern Allergy Conference - New Castle News
Brokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) Price Target at $30.00 - Defense World
Price T Rowe Associates Inc. MD Buys 2,878 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Cantor Fitzgerald Analysts Lower Earnings Estimates for ATXS - Defense World
Wedbush Lowers Earnings Estimates for Astria Therapeutics - Defense World
Q2 EPS Estimate for Astria Therapeutics Lowered by Analyst - Defense World
Astria Therapeutics’ (ATXS) “Overweight” Rating Reiterated at Cantor Fitzgerald - Defense World
FMR LLC Reduces Holdings in Astria Therapeutics Inc - GuruFocus
(ATXS) Technical Data - news.stocktradersdaily.com
Astria Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Analysts Offer Insights on Healthcare Companies: Astria Therapeutics (ATXS), Aquestive Therapeutics (AQST) and Olema Pharmaceuticals (OLMA) - The Globe and Mail
Astria Therapeutics Reports Increased Loss Amid Rising R&D Costs - TipRanks
Analyst Reiterates Overweight Rating for ATXS with Stable Price Target | ATXS Stock News - GuruFocus
Here's Why We're Not Too Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Situation - Yahoo Finance
Astria Therapeutics Inc Stock (ATXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):